Transfer of oncogene in colon cancer cells demonstrated
Posted: 22 July 2019 | Drug Target Review | No comments yet
A new study has shown that proteins derived from the oncogene, KRAS, can transfer between colon cancer cells.


Dr Emil Lou and his research team have demonstrated that proteins derived from the oncogene KRAS have the ability to transfer between colon cancer cells via long cellular skyway-like extensions called ‘tunneling nanotubes’. According to the researchers, inhibiting these signals may be a target for treatment.
The oncogene, KRAS, is implicated in driving cancer, including its origin and growth patterns in 30 percent of all cancers and contributes to tumours becoming drug-resistant. The study examined what happens when a normal form of the protein mutates. The researchers found that the transfer of KRAS caused the surrounding cells to behave in a more cancerous, invasive manner that is more likely to be resistant to standard drugs.
“Most aggressive metastatic colon tumours in patients will develop drug resistance. It’s not a matter of ‘if’, but a matter of ‘when’ for most patients and that’s a big challenge in this field,” said Dr Lou, Assistant Professor of Medicine, Division of Hematology, Oncology and Transplantation, University of Minnesota Medical School. “We speculate that cutting off the line of communication for transfer of vital signals might be a novel therapeutic strategy in addition to standard-of-care chemotherapy.”
Biomarkers are redefining how precision therapies are discovered, validated and delivered.
This exclusive expert-led report reveals how leading teams are using biomarker science to drive faster insights, cleaner data and more targeted treatments – from discovery to diagnostics.
Inside the report:
- How leading organisations are reshaping strategy with biomarker-led approaches
- Better tools for real-time decision-making – turning complex data into faster insights
- Global standardisation and assay sensitivity – what it takes to scale across networks
Discover how biomarker science is addressing the biggest hurdles in drug discovery, translational research and precision medicine – access your free copy today
The researchers hope that these findings will help devise better recognition of ways to revise clinical trial strategies to overcome biological resistance at the cellular level. “This study opens new avenues to fully understand the effects of the transfer of KRAS in colon and other similar cancers driven by KRAS,” Dr Lou continued.
Research into the next steps also will entail figuring out how to cut off that communication.
The study was published in Cancers.
Related topics
Cell Cultures, Drug Development, Oncology, Protein
Related conditions
Colon cancer
Related organisations
University of Minnesota Medical School
Related people
Dr Emil Lou